UNC2025 is a potent, orally bioavailable Mer/FLT3 dual inhibitor with IC50 of 0.74/0.8 nM, 700-fold less active against Met compared to Mer.

Anizatrectinib is a potent and orally active inhibitor of TrkA kinase with potential for inflammatory disease such as prostatitis.

Emzeltrectinib is a potent, selective neurotrophic factor tyrosine kinase receptor TrkB inhibitor, shows potential for treatment of Trk kinase-mediated tumor.

PTX-BD10-2 (BD10-2) is a selective, brain-penetrant small molecule TrkB/C receptor partial agonist, shows survival-promoting activity.

COB223 is a chemical inhibitor of angiogenesis and tumorigenesis, targets the VEGF signaling pathway upstream of Ras, inhibits endothelial cell migration with IC50 of 5 uM.

NRP1-4 (Neuropilin 1-4) is a highly potent, specific small molecule inhibitor of VEGF-A binding to neuropilin 1 (NRP1) with IC50 of 0.598 nM, reduces calcium and sodium currents through binding to NRP1 and inhibits the effects of VEGF-A.

NRPa-308 is a neuropilin-1 (NRP-1) antagonist, inhibits the VEGF-A165/NRP-1 binding with IC50 of 42 uM, exerts in vitro anti-angiogenic activity.

SYHA1813 is a potent dual inhibitor of CSF1R and VEGFR with IC50 of 19.3, 2.8, 0.3, and 4.3 nM for CSF1R, VEGFR1, 2, and 3, respectively.

CW85319 is a small-molecule compound that enhances Axin2's interaction with GSK3β, shows a high-affinity binding with Axin2 with Kd of 5.8 uM.

iCRT-3 is a selective, cell-permeable β-catenin responsive transcription (CRT) inhibitor with IC50 of 8.2 nM.

IMU1003 (IMU-1003) is a small molecule inhibitor of Wnt/β-catenin signaling, decreases β-catenin levels and inhibits target gene expression that promotes cancer cell proliferation.

AB668 is a selective, bivalent Casein Kinase 2 (CK2) inhibitor targeting the ATP site and the αD pocket, AB668 inhibits the CK2 holoenzyme with Ki value of 41 nM (IC50=65 nM).

CKR-49-17 is a potent, allosteric small molecule activator of CK1γ2 with Kd value of 180 nM in MST assays.

FL-1607 is a novel Fam20C inhibitor with potent anti-proliferative effects on TNBC cells, induces apoptosis and inhibits migration in MDA-MB-468 cells.

SGC-CK2-1 analog 2h is potent, selective and in vivo active inhibitor of casein kinase 2α (CSNK2A, CK2α) with pIC50 of 7.5 and 7.7 against CSNK2A1 and CSNK2A2, respectively.

SR-4133 (SR4133) is a potent and highly selective CK1ε isoform inhibitor with IC50 of 58 nM, no significant acitivity agianst CK1δ (IC50>10,000 nM).

BMD4702 is a small molecule Dishevelled (Dvl) PDZ domain with binding Kd of 186 nM.

BMD4722 is a highly potent, small-molecule inhibitor of Dvl-CXXC5 interaction with IC50 of 2.59 uM, directly binds to the Dvl PDZ domain (Kd=22.3 uM).

NPL-4011 is a specific small molecule inhibitor of PDZ domain of human Dvl1 (Dvl1-PDZ) with KD vaule of 34.5 uM in NMR titration experiments.

MDB5 is a potent hedgehog (Hh) signaling pathway inhibitor, exhibits stronger inhibition of the Hh pathway and anticancer effect in vitro and vivo than GDC-0449.

Picoberin is a highly potent (low picomolar) inhibitor of purmorphamine- and Sonic Hedgehog (Shh)-induced osteogenesis with IC50 of 3 pM, acts as an AhR agonist and induces the expression of AhR target genes, thereby suppressing osteoblast differentiation

aNDR1 (NDR1 agonist) is a specific small-molecule agonist of Nuclear Dbf2-related kinase 1 (NDR1, STK38), specifically inhibits CRPC cells and promotes kinase activity of NDR1.